Deutscher Gesundheitsbericht Diabetes 2018 (https://www.diabetesde.org/system/files/documents/gesundheitsbericht_2018.pdf)

KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. In: Kidney Disease: Improving Global Outcomes [KDIGO] CKD Work Group (Hrsg.): Kidney Int. Suppl. 3, Nr. 1, 2013, S. 1–150 (KDIGO CKD 2012 [PDF]).Google Scholar

Bakris et al. Treatment of diabetic kidney disease. https://www.uptodate.com/contents/treatment-of-diabetic-kidney-disease

Umanath et al. Update on Diabetic Nephropathy: CoreCurriculum 2018. Am J Kidney Dis. 71(6):884–895. Published onlineFebruary 2, 2018CrossRefGoogle Scholar

Mosenzon et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606–617.CrossRefGoogle Scholar

Wanner et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117–28.CrossRefGoogle Scholar

Perkovic et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295–2306.CrossRefGoogle Scholar

Thomas et al. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018 Oct;61(10):2098–2107CrossRefGoogle Scholar

Zelniker TA et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;339:31–39CrossRefGoogle Scholar

https://clinicaltrials.gov/Empagliflozin bzw. https://clinicaltrials.gov/dapagliflozin

Peters AL. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015 Sep;38(9):1687–93.CrossRefGoogle Scholar